Author:
Runde V.,Aul C.,Ebert A.,Feinendegen L. E.,Schneider W.
Publisher
Springer Berlin Heidelberg
Reference16 articles.
1. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W (1992) Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6: 52–59
2. Aul C, Schneider W (1989) The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 64: 1812–1818
3. Vadhan-Raj S, Keating M, Le Maistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU (1987) Effects of recombinant human granulocytemacrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1552
4. Ganser A, Seipelt G, Lindemann A, Ottmann OG, Falk F, Eder M, Herrmann F, Becher R, Höffken K, Büchner T, Klausmann M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D (1990) Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76: 455–462
5. Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg PL (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76: 36–43